PFAS Chemical Test
Monitor exposure to industrial perfluoroalkyl and polyfluoroalkyl chemicals, commonly called “PFAS”
The term PFAS encompasses thousands of per-and polyfluoroalkl chemicals that are widely used in consumer goods and industrial products for their non-stick properties.
Common applications include:
- Fast food packaging
- Outdoor gear
- Floor polishes
- Firefighting agents
The unique chemical structure of PFAS makes them difficult to break down, causing them to accumulate in the environment, wildlife, and human body for decades.
Once inside the body, PFAS have a strong binding affinity to plasma and serum proteins and bioaccumulate in the blood. Studies also show the bioaccumulation of PFAS in the lungs, kidneys, liver, and bones.
As individuals of all ages and stages of life are exposed to PFAS, many may benefit from monitoring their exposure to PFAS.
Not Available in New York State
Only healthcare providers licensed in their state may order laboratory testing.
*Vibrant Wellness does not participate in, take assignment, or accept any private insurance. We do not provide super bills and cannot assist with claim resolution for laboratory tests or consultations.
- Perfluorooctanoic acid (PFOA)
- Perfluorohexane Sulfonic Acid (PFHxS)
- Perfluorononanoic acid (PFNA)
- Perfluorodecanoic acid (PFDeA)
- Perfluoroundecanoic acid (PFUnA)
- Perfluorododecanoic acid (PFDoA)
- Perfluorotridecanoic acid (PFTrDA)
- Perfluorotetradecanoic acid (PFTeDA)
- Perfluorobutanoic acid (PFBA)
- Perfluorohexanoic acid (PFHxA)
- Perfluoropentanoic acid (PFPeA)
- Perfluoroheptanoic acid (PFHpA)
- Perfluorooctane sulfonic acid (PFOS)
- Perfluoro-n-[1,2-13C2] hexanoic acid (MPFHxA)
- Perfluoro-[1,2-13C2] octanoic acid (M2PFOA)
- Perfluoro-1-[1,2,3,4-13C4] octanesulfonic acid (MPFOS)
- Perfluoro-n-[1,2-13C2] decanoic acid (MPFDA)
- Perfluoro-1-heptane sulfonic acid (PFHpS)
- 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propanoate (GenX/HPFO-DA)
- Dodecafluoro-3H-4,8-dioxanoate (NaDONA)
- 9-chlorohexadecafluoro-3-oxanonane-1-sulfonate (9Cl-PF3ONS)
Research on the health harms of PFAS is widely available for many long-chain PFAS, with much of the focus on PFOA and PFOS.
Increasing research indicates PFAS demonstrates the potential for harm across endocrine, neurological, respiratory, immune, urinary, gastrointestinal, reproductive, and cardiovascular systems.
The following specific conditions have been studied in relation to general PFAS exposure:
- Asthma: There is limited evidence that in utero and early life exposure to PFAS increases the risk of infections, allergies, asthma, and atopic dermatitis.
- Cancer: The International Agency for Research on Cancer (IARC) classified perfluorooctanoic acid, PFOA, a legacy PFAS, as a possible human carcinogen. The most evidence-based associations with PFOA and cancer are for kidney and testicular cancer. There are also associations in the literature between PFAS and prostate cancer.
- Diabetes: Studies show PFAS appear to behave as potential diabetogens. They can affect PPAR (peroxisome proliferator-activated) receptors that regulate adipocyte differentiation and lipid and glucose homeostasis.
- Hyperlipidemia: Numerous studies show a positive association between elevated PFAS levels and serum lipids, notably LDL and total cholesterol.
- Male infertility: Preclinical studies and epidemiological studies suggest PFAS exposure affects testosterone levels and semen quality, potentially due to toxicity to Leydig cells and changes in levels of steroidogenic enzymes.
- Female infertility: Studies suggest that PFAS, found in follicular fluid, may contribute to fertility issues and affect oocyte development.
- Kidney Disease: Numerous epidemiological studies report an association between exposure to PFAS and reduced kidney function or kidney cancer. Toxicology studies demonstrate structural alterations in the proximal tubules of the nephron and dysregulated metabolic pathways, amongst other mechanisms.
- Liver Disease: Several epidemiological studies report an association between increased PFOA and elevated transaminases. Additional studies on multiple PFAS report changes in liver biomarkers, including transaminases, bilirubin, and GGT.
- Lower infant birth rate: Low birth weight is a consistently reported adverse pregnancy outcome in epidemiological and animal studies relating to gestational PFAS exposure. Studies have found this result in PFOA and several other legacy PFAS.
- Obesity: At least 15 studies have reported positive associations between overweight or obesity and the exposure to at least one PFAS. The studies span many geographic regions and diverse age groups, including maternal exposure and childhood obesity, as well as adults. Mechanisms underlying this may relate to altered leptin levels and other metabolic dysregulations.
- Pre-eclampsia: Several epidemiologic studies have found positive associations between maternal exposure to PFAS and pre-eclampsia. Some research suggests this is related to the impairment of placental function, though the exact mechanism has yet to be fully elucidated.
- Thyroid disease: Studies have found associations with elevated PFOS and PFOA, an increased risk of thyroid disease, and associated alterations in TSH and thyroid hormone levels. In vitro and animal studies support a thyroid-disrupting effect of both old and new-generation PFAS.
- Ulcerative Colitis: PFOA has been shown to have a significant, positive association with ulcerative colitis in highly exposed individuals, though mechanisms remain unclear.
What symptoms are related to chronic PFAS exposure?
Human exposure to PFAS has been associated with adverse effects on the immune, endocrine,
metabolic, and reproductive systems (including fertility and pregnancy outcomes), and increased risk for
Once exposed, PFAS is widely distributed throughout the body, accumulating mainly in the kidneys,
liver, and blood since it can bind to albumin. Rates of elimination vary across the type of compound and
animal species with differences in age and sex, but humans typically eliminate these substances through
urine. Some elimination half-lives include 72–81 h for PFBA, 2.1–8.5 years for PFOA, and 3.1–7.4 years
for PFOS. The Agency for Toxic Substances and Disease Registry (ATSDR) has conducted an extensive
literature review of epidemiological studies involving PFOA, PFOS, and 12 other PFAS that suggest links
between PFAS exposure and health outcomes in humans.
Recommended Tests to Consider